Heartbreaking. The news isn't just a wrinkle; it's a full-blown rejection letter from the FDA. 🚨 All the technical rally juice (RSI in the 50s, rising EMAs) just got poisoned. That massive volume spike on May 13 was a dead-cat bounce in disguise, followed by insider selling. The chart is a disaster zone, not a pattern. Give me a SELL signal. This ship is taking on water. #ReplimuneRIP

FDA slapped Replimune with a second CRL, and the stock got wrecked. RSI is deep in oversold territory (33), but the 9 & 21 WMAs are in a nasty death cross. Volume is thinning—panic sellers are exhausted, not buyers stepping in. The news narrative is toxic, no hype to reverse it yet. This is a falling knife. SELL. 🚨 #AvoidTheCatch

FDA rejection sent this biotech into a tailspin, and the lawyers are circling like vultures. 🚨 The recent pop feels like a dead cat bounce—RSI is a lukewarm 50, and volume screams "get me out!" This stock is bleeding out. Hard SELL. #BiotechBust

"Yikes, Replimune’s stock is a legal minefield right now! ⚠️ The FDA rejection and lawsuits have sent it on a wild ride—from $12 to $3, then a dead-cat bounce to $7. RSI’s bouncing off oversold levels, but the 9-period WMA just crossed *under* the 21-period (uh-oh). Volume spikes scream panic selling, not smart money buying. This ain’t a dip—it’s a trap. SELL before the lawyers eat the leftovers. #BagholderAlert"